AVEO Pharmaceuticals to Participate in Leerink Swann Solid Tumors Roundtable Conference
CAMBRIDGE, MA, May 2, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Leerink Swann Solid Tumors Roundtable Conference on Friday, May 9, 2008 at 10:20 a.m. (ET) at the Grand Hyatt in New York City. In addition, Murray Robinson, Ph.D., senior vice president, oncology, at AVEO Pharmaceuticals will participate in the conference’s expert panel discussion titled “Novel Targeted Agents for Cancer –What Target and Which Pathway?” on May 9, 2008 at 8:35 a.m. (ET).
AVEO is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company's website at http://www.aveopharma.com/.